Exendin‐4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX‐1 and HNF3β transcription factors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Exendin‐4 (EX‐4), a long acting agonist of GLP‐1, induces an endocrine phenotype in Capan‐1 cells. Under culture conditions which include serum, ∼10% of the cells contain insulin and glucagon. When exposed to EX‐4 (0.1 nM, up to 5 days), the number of cells containing insulin and glucagon increased to ∼40%. Western blot analysis detected a progressive increase in protein levels of glucokinase and GLUT2 over 3 days of EX‐4 treatment. We explored the sequence of activation of certain transcription factors known to be essential for the beta cell phenotype: PDX‐1, Beta2/NeuroD, and hepatocyte nuclear factor 3β (HNF3β). Double immunostaining showed that PDX‐1 coexisted with insulin and glucagon in EX‐4‐treated cells. Treatment caused an increase in PDX‐1 protein levels by 24 h and induced its nuclear translocation. Beta2/NeuroD protein levels also increased progressively over 24 h. HNF3β protein level increased twofold as early as 6 h after EX‐4 treatment. EMSA results indicated that EX‐4 caused a 12‐fold increase in HNF3β binding to PDX‐1 promoter area II. Beta2/NeuroD protein levels progressively increased after 24 h treatment. Differentiation to insulin‐producing cells was also seen when Capan‐1 cells were transfected with pdx‐1, with 80% of these cells expressing insulin 3 days after transfection. PDX‐1 antisense totally inhibited such conversion. During the differentiation of duct cells to endocrine cells, cAMP levels (EX‐4 is a ligand for the GLP‐1, G‐protein coupled receptor) and MAP kinase activity increased. Our results indicate that EX‐4 activates adenylyl cyclase and MAP kinase which, in turn, may lead to activation of transcription factors necessary for an endocrine phenotype. Published 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 2×
“We, and others (Buteau et al., 1999), have previously shown that GLP-1 upregulates the expression of PDX-1, a homeodomain protein, necessary for pancreatic development (Wang et al., 1999).”
Background
Cited by
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Glucose, entering via GLUT2 transporters, is rapidly phosphorylated to glucose 6-phosphate by glucokinase and is subsequently metabolized in mitochondria, leading to ATP formation, changes in the ATP/ADP ratio, and closure of the KATP channels, as described above.”
BackgroundResultInfluentialSelf-citationMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Self-citationBrubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
“Finally, GLP-1 was shown to induce neural differentiation of rat pheochromocytoma cells (17) and endocrine differentiation of human pancreatic adenocarcinoma cells (26).”
BackgroundMethodResultInfluentialAnti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“In addition, HNF3β expression is increased earlier than Pdx-1, and HNF3β binds to the pdx-1 gene promoter, suggesting that HNF3β and Pdx-1 play an important role in exendin-4-mediated pancreatic duct cells differentiation to insulin- or glucagon-secreting endocrine cells [84].”
BackgroundDrucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“GLP-1 or exendin-4 treatment can convert rat or human pancreatic exocrine cells into glucagon-, insulin-, or pancreatic polypeptide-containing cells, and acinar pancreatic cells can differentiate into insulin-producing cells through PKC, MAPK signaling, and pancreatic and duodenal homeobox 1 (Pdx-1) regulation [76].”
BackgroundIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
Bray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Metadata
- Authors
- Zhou, J., Pineyro, M. A., Wang, X., Doyle, M. E., & Egan, J. M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2002-07-08
- Volume
- 192
- Issue
- 3
- Pages
- 304-314
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2098812327
- Cited by
- 95
- References
- 2
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.